Approximately 10% of CCA express HER2, with higher rates observed in extrahepatic compared to intrahepatic tumors13, for which there are data supporting the use of the HER2-targeting ADC trastuzumab deruxtecan (T-DXd), now approved in a tumor-agnostic setting14. Here, ERBB2 is linked to neoplasm.